Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.6%

Neg 0% Neu 89.6% Pos 0%

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.

Comments

No comments yet. Be the first!